A cholesterol-lowering VLP vaccine that targets PCSK9.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Vaccine

• Publication date

  2015-10-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2015.09.044PMID 26413878PMCID PMC4609631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.

  2015cited by this paper
• Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Vaccination against Alzheimer disease

  2014cited by this paper
• Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management

  2014cited by this paper
• Active immunotherapy for chronic diseases.

  2013cited by this paper
• An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.

  2013cited by this paper
• A Vaccine against CCR5 Protects a Subset of Macaques upon Intravaginal Challenge with Simian Immunodeficiency Virus SIVmac251

  2013cited by this paper
• Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice

  2012cited by this paper
• Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates

  2012cited by this paper
• Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial.

  2012cited by this paper
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  2012cited by this paper
• An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

  2012cited by this paper
• How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?

  2012cited by this paper
• VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus

  2012cited by this paper
• Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

  2011cited by this paper
• A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2

  2011cited by this paper
• A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

  2009cited by this paper
• Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.

  2008cited by this paper
• Molecular basis for LDL receptor recognition by PCSK9

  2008cited by this paper
• Virus-Like Display of a Neo-Self Antigen Reverses B Cell Anergy in a B Cell Receptor Transgenic Mouse Model1

  2008cited by this paper
• Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 Published, JLR Papers in Press, November 21, 2007.

  2008cited by this paper
• Characterization of novel mutations in the catalytic domain of the PCSK9 gene

  2008cited by this paper
• The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.

  2007cited by this paper
• Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

  2007cited by this paper
• A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

  2007cited by this paper
• Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis Published, JLR Papers in Press, April 20, 2007.

  2007cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006cited by this paper
• Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

  2006cited by this paper
• Contemporary management of dyslipidemia in high-risk patients: targets still not met.

  2006cited by this paper
• Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses.

  2006cited by this paper
• Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

  2005cited by this paper
• Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• NARC-1/PCSK9 and Its Natural Mutants

  2004cited by this paper
• Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

  2004cited by this paper
• Mouse models of experimental atherosclerosis.

  2004cited by this paper
• Induction of Autoantibodies to CCR5 in Macaques and Subsequent Effects upon Challenge with an R5-Tropic Simian/Human Immunodeficiency Virus

  2004cited by this paper
• Therapeutic vaccination for chronic diseases: a new class of drugs in sight

  2004cited by this paper
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

  2003cited by this paper
• Risk for myopathy with statin therapy in high-risk patients.

  2003cited by this paper
• Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

  2003cited by this paper
• A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.

  2002cited by this paper
• Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

  1999cited by this paper

• Emerging strategies for advancing peptide vaccines

  2026cites this paper
• The role of lipids and lipids lowering drugs in human papillomavirus (HPV) and HPV-associated cancers

  2025cites this paper
• Evaluating the effect of the antiPCSK9 vaccine on systemic inflammation and oxidative stress in an experimental mouse model

  2025cites this paper
• Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals.

  2025cites this paper
• Targeting of phosphorylated tau at threonine 181 by a Qβ virus‐like particle vaccine is safe, highly immunogenic, and reduces disease severity in mice and rhesus macaques

  2025cites this paper
• pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model

  2025influential citation
• Two doses of Qβ virus like particle vaccines elicit protective antibodies against heroin and fentanyl

  2025cites this paper
• Engineering chimeric PCSK9 for a vaccine against atherosclerosis

  2025cites this paper
• Mitigating atherosclerosis: Integrating vaccines with gene targets

  2025cites this paper
• The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: From the first cardiovascular disease risk-reducing therapies to the novel challenging strategies.

  2025cites this paper
• Immunotherapy and vaccine-based approaches for atherosclerosis prevention: a systematic review study

  2025cites this paper
• Transforming hypercholesterolemia management: Spotlight on PCSK9 peptide vaccines

  2024cites this paper
• RETRACTED ARTICLE: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection

  2024cites this paper
• Dyslipidemia: A Narrative Review on Pharmacotherapy

  2024cites this paper
• VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys

  2024cites this paper
• Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?

  2024cites this paper
• Bacteriophage Virus-Like Particles: Platforms for Vaccine Design.

  2024cites this paper
• A two-dose regimen of Qβ virus-like particle-based vaccines elicit protective antibodies against heroin and fentanyl

  2024cites this paper
• PCSK9 inhibitors: The earlier the better?

  2024cites this paper
• Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments

  2024cites this paper
• Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathy

  2024cites this paper
• Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia

  2024cites this paper
• The role of PCSK9 in heart failure and other cardiovascular diseases—mechanisms of action beyond its effect on LDL cholesterol

  2024cites this paper
• Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?

  2024cites this paper
• Cholesterol reduction by immunization with a PCSK9 mimic

  2024cites this paper
• The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment

  2024cites this paper
• Repurposed drugs as PCSK9-LDLR disruptors for lipid lowering and cardiovascular disease therapeutics

  2024cites this paper
• PCSK9 in metabolism and diseases.

  2024cites this paper
• Experimental VLP vaccine displaying a furin antigen elicits production of autoantibodies and is well tolerated in mice

  2024cites this paper
• A method for mapping the linear epitopes targeted by the natural antibody response to Zika virus infection using a VLP platform technology.

  2023cites this paper
• A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood.

  2023cites this paper
• PCSK9 inhibitors: current status and emerging frontiers in lipid control

  2023cites this paper
• PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system

  2023cites this paper
• A virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in non-human primates

  2023cites this paper
• PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines

  2023cites this paper
• TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy.

  2023cites this paper
• Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol

  2023cites this paper
• A Virus-like particle-based bivalent PCSK9 vaccine lowers LDL-cholesterol levels in Non-Human Primates

  2023cites this paper
• Novel and future lipid-modulating therapies for the prevention of cardiovascular disease

  2023cites this paper
• The evolving landscape of PCSK9 inhibition in cancer.

  2023cites this paper
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system

  2023cites this paper
• Two decades of vaccine development against atherosclerosis.

  2023cites this paper
• Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice.

  2022cites this paper
• A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines

  2022cites this paper
• PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and their Future Perspectives.

  2022cites this paper
• ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis

  2022cites this paper
• The immunogenic potential of PCSK9 peptide vaccine in mice.

  2022cites this paper
• Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines

  2022cites this paper
• Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications

  2022cites this paper
• A Comprehensive Review of PCSK9 Inhibitors

  2022cites this paper
• Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines

  2022cites this paper
• Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review

  2022cites this paper
• Modulating Autoimmunity against LDL: Development of a Vaccine against Atherosclerosis

  2021cites this paper
• PCSK9 as a new player in cancer: New opportunity or red herring?

  2021cites this paper
• PCSK9 inhibition-based therapeutic approaches: an immunotherapy perspective.

  2021cites this paper
• Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells

  2021cites this paper
• The Multifaceted Biology of PCSK9

  2021cites this paper
• PCSK9 and cancer: Rethinking the link.

  2021cites this paper
• A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice

  2021cites this paper
• RNA Phage VLP-Based Vaccine Platforms

  2021cites this paper
• Nanocarrier-based vaccine delivery systems for synthetic peptide vaccines

  2021cites this paper
• A Single‐Dose, Implant‐Based, Trivalent Virus‐like Particle Vaccine against “Cholesterol Checkpoint” Proteins

  2021cites this paper
• Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine

  2021cites this paper
• Pleiotropic Effects of PCSK-9 Inhibitors

  2021cites this paper
• Novel expression of coat proteins from thermophilic bacteriophage ΦIN93 and evaluation for assembly into virus-like particles.

  2021cites this paper
• Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates

  2021cites this paper
• Development of Bacteriophage Virus-Like Particle Vaccines Displaying Conserved Epitopes of Dengue Virus Non-Structural Protein 1

  2021cites this paper
• Virus-Like Particle Based-Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide

  2020cites this paper
• Factors That Govern the Induction of Long-Lived Antibody Responses

  2020cites this paper
• Opportunities for an atherosclerosis vaccine: From mice to humans.

  2020cites this paper
• Coronary Artery Disease: Therapeutics and Drug Discovery

  2020cites this paper
• Drug Discovery for Coronary Artery Disease.

  2020cites this paper
• Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines

  2020cites this paper
• The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease

  2020cites this paper
• Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

  2020cites this paper
• Biocommunication of Phages

  2020cites this paper
• ssRNA Phages: Life Cycle, Structure and Applications

  2020cites this paper
• Vaccination with VLPs Presenting a Linear Neutralizing Domain of S. aureus Hla Elicits Protective Immunity

  2020cites this paper
• Novel ssRNA phage VLP platform for displaying foreign epitopes by genetic fusion.

  2020cites this paper
• Vaccines Targeting PSCK9 for the Treatment of Hyperlipidemia

  2020cites this paper
• Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy.

  2020cites this paper
• In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.

  2020cites this paper
• Peptidic vaccines: The new cure for heart diseases?

  2020cites this paper
• Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide

  2020cites this paper
• Regulation of Lipoprotein Homeostasis by Self-Assembling Peptides.

  2020cites this paper
• Biological drug and drug delivery-mediated immunotherapy

  2020cites this paper
• P4 Medicine or O4 Medicine? Hippocrates Provides the Answer.

  2019cites this paper
• Keep recycling going: New approaches to reduce LDL-C.

  2019cites this paper
• Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries

  2019cites this paper
• Effects of immunisation against PCSK9 in mice bearing melanoma

  2019cites this paper
• Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges

  2019cites this paper
• Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?

  2019cites this paper
• Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis

  2019cites this paper
• Self‐Albumin Camouflage of Carrier Protein Prevents Nontarget Antibody Production for Enhanced LDL‐C Immunotherapy

  2019cites this paper
• Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system.

  2019cites this paper
• Genetics of Common, Complex Coronary Artery Disease.

  2019cites this paper
• Engineering the PP7 Virus Capsid as a Peptide Display Platform.

  2019cites this paper
• Leading Edge Review GeneticsofCommon , ComplexCoronaryArteryDisease

  2019cites this paper
• Targeting PCSK9: Implications for basic science and upcoming challenges.

  2019cites this paper
• PCSK9 Hapten Multicopy Displayed onto Carrier Protein Nanoparticle: An Antiatherosclerosis Vaccine.

  2019cites this paper